Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...
Vedolizumab is associated with lower venous thromboembolism and cardiovascular event risk than TNF inhibitors in UC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results